ReviewOncology reports2026
T cell fate regulation in EBV‑associated nasopharyngeal carcinoma (Review).
Review in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma, a malignancy associated with Epstein‑Barr virus, presents a complex immune editing landscape in which T cell fate determination carries out a central role. T cell metabolic exhaustion, Epstein‑Barr virus antigen presentation and tertiary lymphoid structure remodeling are important in the context of tumor immune evasion. Although individual mechanisms have been extensively studied, their interplay and collective contribution to immune editing remain incompletely understood. The present review summarizes the current advances in nasopharyngeal carcinoma immune editing, with a focus on the molecular network underlying T cell fate decisions. How these mechanisms can be leveraged to develop novel immunotherapeutic strategies is further discussed. By integrating recent findings, the present review aims to offer new insights into the intricate immune landscape of nasopharyngeal carcinoma and to provide a theoretical basis for improving immunotherapy efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.